Northwestern Mutual Wealth Management Co. increased its position in SPDR S&P Biotech (NYSEARCA:XBI) by 31.9% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,714 shares of the exchange traded fund’s stock after purchasing an additional 19,278 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in SPDR S&P Biotech were worth $6,152,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Newman Dignan & Sheerar Inc. grew its stake in SPDR S&P Biotech by 0.6% in the second quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock worth $638,000 after purchasing an additional 50 shares in the last quarter. FineMark National Bank & Trust grew its stake in SPDR S&P Biotech by 7.4% in the second quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock worth $402,000 after purchasing an additional 360 shares in the last quarter. Cornerstone Advisory LLP grew its stake in SPDR S&P Biotech by 109.0% in the second quarter. Cornerstone Advisory LLP now owns 14,628 shares of the exchange traded fund’s stock worth $1,129,000 after purchasing an additional 7,628 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in SPDR S&P Biotech by 10.9% in the second quarter. Janney Montgomery Scott LLC now owns 98,057 shares of the exchange traded fund’s stock worth $7,568,000 after purchasing an additional 9,655 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its stake in SPDR S&P Biotech by 14.0% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 26,186 shares of the exchange traded fund’s stock worth $2,021,000 after purchasing an additional 3,212 shares in the last quarter.

SPDR S&P Biotech (XBI) traded down 0.63% during trading on Friday, reaching $83.82. The company had a trading volume of 2,460,707 shares. The firm has a 50-day moving average price of $79.03 and a 200 day moving average price of $73.45. SPDR S&P Biotech has a 12-month low of $53.15 and a 12-month high of $84.90.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/10/northwestern-mutual-wealth-management-co-boosts-position-in-spdr-sp-biotech-xbi.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Stock Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related stocks with our FREE daily email newsletter.